Marinomed's Antiviral Effective in Clinical Trial for CommonCold - Study published in Respiratory Research
Vienna, Austria, 11 August 2010 - Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that a pilot clinical trial examining the Company’s marketed antiviral nasal spray, which contains Carrageenan, was effective as a treatment against the common cold. The study showed a reduction in symptoms, which was paralleled by strong antiviral activity. The results of the study, conducted at the Common Cold and Nasal Research Centre, Cardiff University (UK), has been published on 10th August 2010 in the journal Respiratory Research.
The trial was a double-blind placebo-controlled pilot trial involving 35 adult subjects suffering from the early symptoms of the common cold. Each subject received either a Carrageenan-containing or a saline placebo nasal spray three times per day for four days. At the end of the trial, those that had received the Carrageenan nasal spray had significantly fewer cold symptoms (p=0.046) and decreased viral load in nasal lavages (p=0.009). The safety of the Carrageenan nasal spray was also confirmed.
Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: “This remarkable treatment is the first demonstrably effective therapy that challenges the viral causes of the common cold. We are delighted with these positive clinical results, especially because this is the first product to emerge from our technology platform.”
Marinomed’s antiviral nasal spray using Carrageenan is the
first product based on the Company’s innovative technology
platform mavirex. The nasal spray is currently marketed in Austria
and was recently licensed to Boehringer Ingelheim for Europe, CIS
and South America. The paper entitled “Efficacy and safety of
an antiviral Iota-Carrageenan nasal spray: a randomized,
double-blind, placebo controlled pilot study in volunteers with
early symptoms of the common
cold
- ends -
About Marinomed Biotechnologie GmbH Marinomed Biotechnologie
GmbH was founded in 2006 and develops therapies against respiratory
diseases based on an innovative technology platform. The usability
of this safe and effective technology has been proven by its first
marketed product: an anti-viral nasal spray. The huge potential of
the technology is reflected by Marinomed´s additional
products concentrating on influenza, combination products for
asthmatics and other high-risk patients. In addition, the Company
develops a novel treatment against type I allergy and autoimmune
diseases. Marinomed Biotechnologie GmbH is a spin-off from the
Veterinary University Vienna and is located in Vienna, Austria. For
further information please visit the website at
www.marinomed.com
Contact: Johanna Uhlmann Business Development Marinomed Biotechnologie GmbH Tel: +43 (0)1 25077 4460 Johanna.Uhlmann@marinomed.comJohanna.Uhlmann@marinomed.com>
Dr. Douglas Pretsell Associate Partner College Hill Tel : +49
(0) 89 5700 1806 Douglas.Pretsell@collegehill.com
Posted: August 2010
